Cargando…

Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma

The efficacy of preoperative neoadjuvant chemoradiotherapy (NAC) in cases of pancreatic cancer with extremely poor prognoses has been reported. In this study, we aimed to identify novel biomarkers that reflect prognoses following chemoradiotherapy using tertiary lymphoid organs (TLO) expressed in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwabara, Shota, Tsuchikawa, Takahiro, Nakamura, Toru, Hatanaka, Yutaka, Hatanaka, Kanako C., Sasaki, Katsunori, Ono, Masato, Umemoto, Kazufumi, Suzuki, Tomohiro, Sato, Osamu, Hane, Yuma, Nakanishi, Yoshitsugu, Asano, Toshimichi, Ebihara, Yuma, Kurashima, Yo, Noji, Takehiro, Murakami, Soichi, Okamura, Keisuke, Shichinohe, Toshiaki, Hirano, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549910/
https://www.ncbi.nlm.nih.gov/pubmed/30997706
http://dx.doi.org/10.1111/cas.14023
_version_ 1783424089596100608
author Kuwabara, Shota
Tsuchikawa, Takahiro
Nakamura, Toru
Hatanaka, Yutaka
Hatanaka, Kanako C.
Sasaki, Katsunori
Ono, Masato
Umemoto, Kazufumi
Suzuki, Tomohiro
Sato, Osamu
Hane, Yuma
Nakanishi, Yoshitsugu
Asano, Toshimichi
Ebihara, Yuma
Kurashima, Yo
Noji, Takehiro
Murakami, Soichi
Okamura, Keisuke
Shichinohe, Toshiaki
Hirano, Satoshi
author_facet Kuwabara, Shota
Tsuchikawa, Takahiro
Nakamura, Toru
Hatanaka, Yutaka
Hatanaka, Kanako C.
Sasaki, Katsunori
Ono, Masato
Umemoto, Kazufumi
Suzuki, Tomohiro
Sato, Osamu
Hane, Yuma
Nakanishi, Yoshitsugu
Asano, Toshimichi
Ebihara, Yuma
Kurashima, Yo
Noji, Takehiro
Murakami, Soichi
Okamura, Keisuke
Shichinohe, Toshiaki
Hirano, Satoshi
author_sort Kuwabara, Shota
collection PubMed
description The efficacy of preoperative neoadjuvant chemoradiotherapy (NAC) in cases of pancreatic cancer with extremely poor prognoses has been reported. In this study, we aimed to identify novel biomarkers that reflect prognoses following chemoradiotherapy using tertiary lymphoid organs (TLO) expressed in the tumor microenvironment. Resected tumor specimens were obtained from 140 pancreatic cancer patients. We retrospectively investigated the clinical relevance of TLO by categorizing patients into those who underwent upfront surgery (surgery first [SF]) and those who received NAC. The immunological elements within TLO were analyzed by immunohistochemistry (IHC). In the IHC analysis, the proportions of CD8+ T lymphocytes, PNAd+ high endothelial venules, CD163+ macrophages and Ki‐67+ cells within the TLO were higher in the NAC group than in the SF group. In contrast, the proportion of programmed cell death‐1+ immunosuppressive lymphocytes within TLO was lower in the NAC group than in the SF group. The NAC group demonstrated favorable prognoses compared with the SF group. In the multivariate analysis, the TLO/tumor ratio was determined as an independent predictive prognostic factor. In conclusion, the administration of preoperative chemoradiotherapy may influence the immunological elements in the tumor microenvironment and result in favorable prognoses in pancreatic ductal adenocarcinoma patients.
format Online
Article
Text
id pubmed-6549910
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65499102019-06-07 Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma Kuwabara, Shota Tsuchikawa, Takahiro Nakamura, Toru Hatanaka, Yutaka Hatanaka, Kanako C. Sasaki, Katsunori Ono, Masato Umemoto, Kazufumi Suzuki, Tomohiro Sato, Osamu Hane, Yuma Nakanishi, Yoshitsugu Asano, Toshimichi Ebihara, Yuma Kurashima, Yo Noji, Takehiro Murakami, Soichi Okamura, Keisuke Shichinohe, Toshiaki Hirano, Satoshi Cancer Sci Original Articles The efficacy of preoperative neoadjuvant chemoradiotherapy (NAC) in cases of pancreatic cancer with extremely poor prognoses has been reported. In this study, we aimed to identify novel biomarkers that reflect prognoses following chemoradiotherapy using tertiary lymphoid organs (TLO) expressed in the tumor microenvironment. Resected tumor specimens were obtained from 140 pancreatic cancer patients. We retrospectively investigated the clinical relevance of TLO by categorizing patients into those who underwent upfront surgery (surgery first [SF]) and those who received NAC. The immunological elements within TLO were analyzed by immunohistochemistry (IHC). In the IHC analysis, the proportions of CD8+ T lymphocytes, PNAd+ high endothelial venules, CD163+ macrophages and Ki‐67+ cells within the TLO were higher in the NAC group than in the SF group. In contrast, the proportion of programmed cell death‐1+ immunosuppressive lymphocytes within TLO was lower in the NAC group than in the SF group. The NAC group demonstrated favorable prognoses compared with the SF group. In the multivariate analysis, the TLO/tumor ratio was determined as an independent predictive prognostic factor. In conclusion, the administration of preoperative chemoradiotherapy may influence the immunological elements in the tumor microenvironment and result in favorable prognoses in pancreatic ductal adenocarcinoma patients. John Wiley and Sons Inc. 2019-05-09 2019-06 /pmc/articles/PMC6549910/ /pubmed/30997706 http://dx.doi.org/10.1111/cas.14023 Text en © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Kuwabara, Shota
Tsuchikawa, Takahiro
Nakamura, Toru
Hatanaka, Yutaka
Hatanaka, Kanako C.
Sasaki, Katsunori
Ono, Masato
Umemoto, Kazufumi
Suzuki, Tomohiro
Sato, Osamu
Hane, Yuma
Nakanishi, Yoshitsugu
Asano, Toshimichi
Ebihara, Yuma
Kurashima, Yo
Noji, Takehiro
Murakami, Soichi
Okamura, Keisuke
Shichinohe, Toshiaki
Hirano, Satoshi
Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
title Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
title_full Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
title_fullStr Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
title_full_unstemmed Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
title_short Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
title_sort prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549910/
https://www.ncbi.nlm.nih.gov/pubmed/30997706
http://dx.doi.org/10.1111/cas.14023
work_keys_str_mv AT kuwabarashota prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT tsuchikawatakahiro prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT nakamuratoru prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT hatanakayutaka prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT hatanakakanakoc prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT sasakikatsunori prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT onomasato prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT umemotokazufumi prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT suzukitomohiro prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT satoosamu prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT haneyuma prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT nakanishiyoshitsugu prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT asanotoshimichi prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT ebiharayuma prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT kurashimayo prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT nojitakehiro prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT murakamisoichi prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT okamurakeisuke prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT shichinohetoshiaki prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma
AT hiranosatoshi prognosticrelevanceoftertiarylymphoidorgansfollowingneoadjuvantchemoradiotherapyinpancreaticductaladenocarcinoma